差動ターゲット多重脊髄刺激 (DETECT)
差動標的多重脊髄刺激: 多施設コホート研究
Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of chronic back and leg pain. Additionally, a subgroup analysis will be performed to evaluate potential differences between paddle/surgical leads versus percutaneous leads.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
-
Antwerp、ベルギー
- ZNA
-
Bruges、ベルギー
- AZ Sint-Jan Brugge-Oostende
-
Bruges、ベルギー
- AZ Sint-Lucas Brugge
-
Hasselt、ベルギー
- Jessa Ziekenhuis
-
Kortrijk、ベルギー
- AZ Groeninge
-
Leuven、ベルギー
- UZ Leuven
-
Lier、ベルギー
- Heilig Hart Ziekenhuis Lier
-
Liège、ベルギー
- Centre Hospitalier Régional (CHR) de la Citadelle
-
Mechelen、ベルギー
- AZ Sint-Maarten
-
Roeselare、ベルギー
- AZ Delta
-
Sint-Niklaas、ベルギー
- Vitaz
-
Turnhout、ベルギー
- AZ Turnhout
-
Wilrijk、ベルギー
- GZA
-
-
Brussels Capital
-
Jette、Brussels Capital、ベルギー、1090
- Universitair Ziekenhuis Brussel
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients with chronic back and leg pain due to Failed Back Surgery Syndrome (FBSS)/Persistent Spinal Pain Syndrome type 2 (PSPS-T2), who will receive treatment with differential target multiplexed (DTM) SCS.
説明
Inclusion Criteria:
- Patients with severe chronic pain (> 5 on numeric rating scale, NRS) for at least 6 months due to FBSS (PSPS T2) and suitable for treatment with DTM SCS according to the treating physician
- Age > 18 years
- Patient has been informed of the study procedures and has given written informed consent
- Patient willing to comply with study protocol including attending the study visits
Exclusion Criteria:
- Expected inability of the patient to receive or properly operate the spinal cord stimulation system
- History of coagulation disorder, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis, or morbus Bechterew
- Active malignancy
- Addiction to drugs, alcohol (>5 units per day) and/or medication
- Evidence of an active disruptive psychiatric disorder or other known condition that may impact perception of pain, compliance to the intervention, and/or ability to evaluate treatment outcome as determined by investigator
- Immune deficiency (e.g. HIV positive, immunosuppressive treatment)
- Life expectancy < 1 year
- Local infection or any other skin disorder at site of incision
- Pregnancy
- Other implanted active medical device
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Spinal cord stimulation
Patients will receive differential target multiplexed spinal cord stimulation |
differential target multiplexed stimulation |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall pain intensity with Visual Analogue Scale (VAS)
時間枠:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Overall pain, defined as a combination of back and leg pain, but not pain from other body parts, measured with the VAS (100mm) |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Visual Analogue Scale (VAS) による腰痛の強度
時間枠:ベースラインスクリーニングとDTM刺激後1ヶ月、6ヶ月、12ヶ月後の評価の間の変化
|
ベースラインスクリーニングとDTM刺激後1ヶ月、6ヶ月、12ヶ月後の評価の間の変化
|
|
|
Visual Analogue Scale (VAS) による脚の痛みの強度
時間枠:ベースラインスクリーニングとDTM刺激後1ヶ月、6ヶ月、12ヶ月後の評価の間の変化
|
ベースラインスクリーニングとDTM刺激後1ヶ月、6ヶ月、12ヶ月後の評価の間の変化
|
|
|
臨床全体的なレスポンダーのステータス
時間枠:ベースラインスクリーニングとDTM刺激後1ヶ月、6ヶ月、12ヶ月後の評価の間の変化
|
ベースラインスクリーニングとDTM刺激後1ヶ月、6ヶ月、12ヶ月後の評価の間の変化
|
|
|
成功した DTM トライアルの割合。
時間枠:最終的な SCS 移植後に評価
|
最終的な SCS 移植後に評価
|
|
|
バッテリー消費量
時間枠:DTM SCS の 1 か月、6 か月、12 か月での登録
|
DTM SCS の 1 か月、6 か月、12 か月での登録
|
|
|
DTM SCS プログラミングに関する技術的な問題の蔓延
時間枠:学習期間全体を通して
|
学習期間全体を通して
|
|
|
DTM SCS 刺激パラメータ
時間枠:DTM SCS の 1 か月、6 か月、12 か月での登録
|
DTM SCS の 1 か月、6 か月、12 か月での登録
|
|
|
Pain medication use
時間枠:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Open question regarding the dosage, frequency and type of pain medication |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Functional disability
時間枠:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The functional disabilities will be assessed with the Oswestry Disability Index (ODI) |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Health related quality of life
時間枠:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Health related quality of life, evaluated with the EuroQol with five dimensions and 5 levels |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Patient global impression of change
時間枠:Evaluated at 1 month, 6 months and 12 months of DTM SCS.
|
Patients will be asked to quantify the impression of change after treatment using the Patient Global Impression of Change scale (PGIC). |
Evaluated at 1 month, 6 months and 12 months of DTM SCS.
|
|
Patients' individual competencies for self-management
時間枠:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Patient activation measure-13 (PAM) is a 13-item instrument which assesses self-reported behaviour, knowledge, and confidence for self-management of one's health. |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Work status
時間枠:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Work status is evaluated with a self-designed questionnaire |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Pain catastrophizing
時間枠:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The Pain Catastrophizing Scale (PCS) will be used to measure the level of pain catastrophizing |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Symptoms of central sensitisation.
時間枠:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The Central Sensitization Inventory is used to measure symptoms of central sensitisation |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Anxiety and Depression.
時間枠:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The hospital Anxiety and Depression Scale (HADS) will measure symptoms of anxiety and depression |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Healthcare utilisation.
時間枠:The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
|
Postoperative healthcare expenditure will be investigated by self-reporting methods. |
The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
|
|
Time spent in body postures
時間枠:The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
|
Based on the AdaptiveStim technology, the time spent in body postures can be recorded. |
The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
|
|
(Serious) adverse events
時間枠:Throughout study period
|
Systematically recording all adverse events |
Throughout study period
|
|
Patient expectations concerning SCS
時間枠:Evaluated at baseline visit
|
Self-constructed open question to evaluate patient expectations about SCS |
Evaluated at baseline visit
|
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- DETECT
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。